Nereus Initiates Combination Clinical Trial for Solid Tumors
Posted on: Monday, 21 April 2008, 09:01 CDT
Nereus Pharmaceuticals has started enrollment in a Phase Ib study evaluating the proteasome inhibitor NPI-0052 in combination with vorinostat in patients with selected solid tumor malignancies.
The open-label study will enroll approximately 40 patients with advanced non-small cell lung cancer, pancreatic cancer or melanoma for whom standard approved therapy is not available. The study follows on positive outcomes from preclinical studies of the combined agents and clinical trials with NPI-0052. Upon successful completion of the Phase Ib trial and determination of the recommended doses for the combined agents, Nereus expects to advance the program into Phase II trials in 2009.
Matthew Spear, chief medical officer of Nereus, said: "Combining complementary anticancer agents to maximize their effects is proven strategy that we are excited to explore with our internally-discovered, second-generation proteasome inhibitor NPI-0052, and we have been particularly impressed with the preclinical results from this combination."
Source: Datamonitor
Related Articles
- Neurocrine Biosciences Completes 'Petal Study' Treatment Phase for Endometriosis
- Nereus Pharmaceuticals Initiates Combination Clinical Trial for Proteasome Inhibitor NPI-0052 in Solid Tumors
- Nereus Pharmaceuticals' NPI-0052 Named One of the Industry's Top Ten Unpartnered Oncology Drug Candidates
- The Multiple Myeloma Research Consortium and Nereus Pharmaceuticals Initiate Clinical Trial Investigating NPI-0052 to Treat Multiple Myeloma
- Callisto Announces Plan to Initiate a Single Agent Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
- Nereus Pharmaceuticals Initiates Phase I Clinical Trial for Anti-Cancer Compound NPI-2358
- Nereus Pharmaceuticals Initiates Phase I Clinical Trial for Anti-Cancer Proteasome Inhibitor
- Heart Disease Study in Phase 2 -- Lifestyles to Be Looked at to See If They Are Cause of Higher Black Cardiac Ills
- Regeneron's VEGF Trap Demonstrates Positive Preliminary Results From Single-Agent Phase 1 Trial in Patients With Advanced Cancer; Results Presented at ASCO Annual Meeting on May 16, 2005
- Keryx Biopharmaceuticals, Inc.: Data From KRX-0401 Single Agent Phase 2 Study in Recurrent Prostate Cancer Presented at the American Society of Clinical Oncology Annual Meeting
 |
 |
User Comments (0)
RSS Feeds